Immunic (IMUX) Q1 2026 earnings summary

Executive summary

• Advanced clinical programs in multiple sclerosis (MS) with vidofludimus calcium, including ongoing Phase 3 ENSURE trials and completed Phase 2 CALLIPER trial showing positive efficacy and safety results, with top-line Phase 3 data expected by end of 2026.

• IMU-856 program completed Phase 1b in celiac disease and is under strategic review for potential partnerships, licensing, or financing.

• IMU-381 remains in preclinical development leveraging the Nurr1 platform for neurologic and autoimmune diseases.

• Leadership changes include a CEO search, appointment of Michael A. Panzara as Chief Medical Officer, and Board refreshment, with Jon Congleton joining the Board.

• Raised $200 million upfront in an oversubscribed private placement, with potential for an additional $200 million, supporting operations through late 2027.

Financial highlights

• Net loss for Q1 2026 was $32.6 million ($1.08 per share), up from $25.5 million ($2.51 per share) in Q1 2025, driven by increased R&D and G&A expenses.

• Operating expenses rose 24% year-over-year to $33.2 million, with R&D up 19% to $25.6 million and G&A up 44% to $7.6 million.

• Interest income increased to $0.8 million due to higher cash balances from recent financings.

• Cash and cash equivalents were $186.6 million as of March 31, 2026, compared to $15.5 million at year-end 2025.

• Accumulated deficit reached $641.2 million as of March 31, 2026.

Outlook and guidance

• Sufficient cash runway to fund operations into late 2027.

• Top-line data from both ENSURE Phase 3 trials expected by end of 2026, with NDA submission planned for mid-2027 and potential regulatory approval in 2028.

• Preparation underway for a Phase 3 program in primary progressive MS, pending regulatory feedback, with initiation planned for later in 2026.

• Ongoing evaluation of strategic alternatives for IMU-856, including potential partnerships or licensing.